Association of PD‑L1 and ZEB‑1 expression patterns with clinicopathological characteristics and prognosis in oral squamous cell carcinoma

Takamaru,Natsumi; Fukuda,Naoyuki; Akita,Kazuya; Kudoh,Keiko; Miyamoto,Youji

doi:10.3892/ol.2022.13195

Association of PD‑L1 and ZEB‑1 expression patterns with clinicopathological characteristics and prognosis in oral squamous cell carcinoma

Authors:
- Natsumi Takamaru
- Naoyuki Fukuda
- Kazuya Akita
- Keiko Kudoh
- Youji Miyamoto
View Affiliations

Affiliations: Department of Oral Surgery, Institute of Biomedical Sciences, Tokushima University Graduate School, Tokushima 770‑8504, Japan
Published online on: January 10, 2022 https://doi.org/10.3892/ol.2022.13195
Article Number: 75

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Programmed cell death‑1 (PD‑1) and its ligand programmed cell death 1 ligand 1 (PD‑L1) are immune checkpoint inhibitors that play an important role in the host immune avoidance mechanism of tumors. The relationship between PD‑L1 expression and malignancy has been reported in various types of cancer, such as lung and gastric cancer. In addition, epithelial‑mesenchymal transition (EMT) of cancer cells is deeply involved in the invasion and metastasis of cancer. It has been reported that zinc finger E‑box binding homeobox 1 (ZEB‑1), an EMT inducer, contributes to metastasis in pancreatic and colon cancer. The present study aimed to investigate the relationship between the expression patterns of two markers, PD‑L1 and ZEB‑1, and clinicopathological characteristics and prognosis of oral squamous cell carcinoma (OSCC). Biopsy or surgical excision specimens from 169 patients with OSCC were used in the present study. Immunohistochemical staining with monoclonal anti‑PD‑L1 antibody and anti‑ZEB‑1 antibody was conducted. Cases with >1% tumor cells positive for PD‑L1 and those with >10% tumor cells positive for ZEB‑1 were considered positive, respectively. The findings revealed that individual expression of PD‑L1 and ZEB‑1 in OSCC was not associated with tumor size, degree of differentiation or Yamamoto‑Kohama invasion pattern classification. However, co‑expression of PD‑L1 and ZEB‑1 was associated with higher cervical lymph node metastasis and a lower survival rate. In conclusion, the results of the present study indicated that co‑expression of PD‑L1 and ZEB‑1 could serve as a potential marker for the prognosis of patients with OSCC.

View Figures

View References

1	Ebrahimi A, Zhang WJ, Gao K and Clark JR: Nodal yield and survival in oral squamous cancer: Defining the standard of care. Cancer. 117:2917–2925. 2011. View Article : Google Scholar : PubMed/NCBI
2	Pardoll DM: The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 22:252–264. 2012. View Article : Google Scholar : PubMed/NCBI
3	Carlsson J, Sundqvist P, Kosuta V, Fält A, Giunchi F, Fiorentino M and Davidsson S: PD-L1 expression is associated with poor prognosis in renal cell carcinoma. Appl Immunohistochem Mol Morphol. 28:213–220. 2020. View Article : Google Scholar : PubMed/NCBI
4	Pei R, Zhang W, Wang S, Huang X and Zou Y: Prognostic value of PD-L1 in patients with hepatocellular carcinoma. Clin Lab. May 1–2019.(Epub ahead of print). doi: 10.7754/Clin.Lab.2018.180839. View Article : Google Scholar : PubMed/NCBI
5	Webb JR, Milne K, Kroeger DR and Nelson BH: PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer. Gynecol Oncol. 141:293–302. 2016. View Article : Google Scholar : PubMed/NCBI
6	Takada K, Toyokawa G, Shoji F, Okamoto T and Maehara Y: The significance of the PD-L1 expression in non-small-cell lung cancer: Trenchant double swords as predictive and prognostic markers. Clin Lung Cancer. 19:120–129. 2018. View Article : Google Scholar : PubMed/NCBI
7	Gheldof A, Hulpiau P, van Roy F, De Craene B and Berx G: Evolutionary functional analysis and molecular regulation of the ZEB transcription factors. Cell Mol Life Sci. 69:2527–2541. 2012. View Article : Google Scholar : PubMed/NCBI
8	Vandewalle C, Van Roy F and Berx G: The role of the ZEB family of transcription factors in development and disease. Cell Mol Life Sci. 66:773–787. 2009. View Article : Google Scholar : PubMed/NCBI
9	Zhang PJ, Sun YT and Ma L: ZEB1: At the crossroads of epithelial-mesenchymal transition, metastasis and therapy resistance. Cell Cycle. 14:481–487. 2015. View Article : Google Scholar : PubMed/NCBI
10	Tsutsumi S, Saeki H, Nakashima Y, Ito S, Oki E, Morita M, Oda Y, Okano S and Maehara Y: Programmed death-ligand 1 expression at tumor invasive front is associated with epithelial-mesenchymal transition and poor prognosis in esophageal squamous cell carcinoma. Cancer Sci. 108:1119–1127. 2017. View Article : Google Scholar : PubMed/NCBI
11	Lin YM, Sung WW, Hsieh MJ, Tsai SC, Lai HW, Yang SM, Shen KH, Chen MK, Lee H, Yeh KT and Chen CJ: High PD-L1 expression correlates with metastasis and poor prognosis in oral squamous cell carcinoma. PLoS One. 10:e01426562015. View Article : Google Scholar : PubMed/NCBI
12	Yao X, Sun S, Zhou X, Zhang Q, Guo W and Zhang L: Clinicopathological significance of ZEB-1 and E-cadherin proteins in patients with oral cavity squamous cell carcinoma. Onco Targets Ther. 10:781–790. 2017. View Article : Google Scholar : PubMed/NCBI
13	Sobin LH and Wittekind C: TNM Classification of Malignant Tumours. 6th edition. John Wiley & Sons Inc.; New York, USA: pp. 22–26. 2002
14	Jakobsson PA, Eneroth CM, Killander D, Moberger G and Mårtensson B: Histologic classification and grading of malignancy in carcinoma of the larynx. Acta Radiol Ther Phys Biol. 12:1–8. 1973. View Article : Google Scholar : PubMed/NCBI
15	Willén R, Nathanson A, Moberger G and Anneroth G: Squamous cell carcinoma of the gingiva. Histological classification and grading of malignancy. Acta Otolaryngol. 79:146–154. 1975. View Article : Google Scholar : PubMed/NCBI
16	Yamamoto E, Miyakawa A and Kohama G: Mode of invasion and lymph node metastasis in squamous cell carcinoma of the oral cavity. Head Neck Surg. 6:938–947. 1984. View Article : Google Scholar : PubMed/NCBI
17	Piffko J, Bánkfalvi A, Ofner D, Rasch D, Joos U and Schmid KW: Standardized demonstration of silver-stained nucleolar organizer regions-associated proteins in archival oral squamous cell carcinomas and adjacent non-neoplastic mucosa. Mod Pathol. 10:98–104. 1997.PubMed/NCBI
18	Burtness B, Harrington KJ, Greil R, Soulières D, Tahara M, de Castro G Jr, Psyrri A, Basté N, Neupane P, Bratland Å, et al: Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): A randomised, open-label, phase 3 study. Lancet. 394:1915–1928. 2019. View Article : Google Scholar : PubMed/NCBI
19	Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ and Choi W: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Cancer Res. 69:5820–5828. 2009. View Article : Google Scholar : PubMed/NCBI
20	Chin D, Boyle GM, Williams RM, Ferguson K, Pandeya N, Pedley J, Campbell CM, Theile DR, Parsons PG and Coman WB: Novel markers for poor prognosis in head and neck cancer. Int J Cancer. 113:789–797. 2005. View Article : Google Scholar : PubMed/NCBI
21	Greaves P and Gribben JG: The role of B7 family molecules in hematologic malignancy. Blood. 121:734–744. 2013. View Article : Google Scholar : PubMed/NCBI
22	Keir ME, Liang SC, Guleria I, Latchman YE, Qipo A, Albacker LA, Koulmanda M, Freeman GJ, Sayegh MH and Sharpe AH: Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 203:883–895. 2006. View Article : Google Scholar : PubMed/NCBI
23	Azuma T, Yao S, Zhu G, Flies AS, Flies SJ and Chen L: B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. Blood. 111:3635–3643. 2008. View Article : Google Scholar : PubMed/NCBI
24	Konishi J, Yamazaki K, Azuma M, Kinoshita I, Dosaka-Akita H and Nishimura M: B7-H1 expression on non-small cell lung cancer cells and its relationship with tumor-infiltrating lymphocytes and their PD-1 expression. Clin Cancer Res. 10:5094–5100. 2004. View Article : Google Scholar : PubMed/NCBI
25	Ohigashi Y, Sho M, Yamada Y, Tsurui Y, Hamada K, Ikeda N, Mizuno T, Yoriki R, Kashizuka H, Yane K, et al: Clinical significance of programmed death-1 ligand-1 and programmed death-1 ligand-2 expression in human esophageal cancer. Clin Cancer Res. 11:2947–2953. 2005. View Article : Google Scholar : PubMed/NCBI
26	Strome SE, Dong H, Tamura H, Voss SG, Flies DB, Tamada K, Salomao D, Cheville J, Hirano F, Lin W, et al: B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res. 63:6501–6505. 2003.PubMed/NCBI
27	Thompson RH, Gillett MD, Cheville JC, Lohse CM, Dong H, Webster WS, Krejci KG, Lobo JR, Sengupta S, Chen L, et al: Costimulatory B7-H1 in renal cell carcinoma patients: Indicator of tumor aggressiveness and potential therapeutic target. Proc Natl Acad Sci USA. 101:17174–17179. 2004. View Article : Google Scholar : PubMed/NCBI
28	Wintterle S, Schreiner B, Mitsdoerffer M, Schneider D, Chen L, Meyermann R, Weller M and Wiendl H: Expression of the B7-related molecule B7-H1 by glioma cells: A potential mechanism of immune paralysis. Cancer Res. 63:7462–7467. 2003.PubMed/NCBI
29	Ghebeh H, Mohammed S, Al-Omair A, Qattan A, Lehe C, Al-Qudaihi G, Elkum N, Alshabanah M, Bin Amer S, Tulbah A, et al: The B7-H1 (PD-L1) T lymphocyte-inhibitory molecule is expressed in breast cancer patients with infiltrating ductal carcinoma: Correlation with important high-risk prognostic factors. Neoplasia. 8:190–198. 2006. View Article : Google Scholar : PubMed/NCBI
30	Thompson RH, Kuntz SM, Leibovich BC, Dong H, Lohse CM, Webster WS, Sengupta S, Frank I, Parker AS, Zincke H, et al: Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res. 66:3381–3385. 2006. View Article : Google Scholar : PubMed/NCBI
31	Nomi T, Sho M, Akahori T, Hamada K, Kubo A, Kanehiro H, Nakamura S, Enomoto K, Yagita H, Azuma M and Nakajima Y: Clinical significance and therapeutic potential of the programmed death-1 ligand/programmed death-1 pathway in human pancreatic cancer. Clin Cancer Res. 13:2151–2157. 2007. View Article : Google Scholar : PubMed/NCBI
32	Zhang L, Xu LJ, Zhu J, Li J, Xue BX, Gao J, Sun CY, Zang YC, Zhou YB, Yang DR and Shan YX: ATM-JAK-PD-L1 signaling pathway inhibition decreases EMT and metastasis of androgen-independent prostate cancer. Mol Med Rep. 17:7045–7054. 2018.PubMed/NCBI
33	Ran J, Lin DL, Wu RF, Chen QH, Huang HP, Qiu NX and Quan S: ZEB1 promotes epithelial-mesenchymal transition in cervical cancer metastasis. Fertil Steril. 103:1606–1614.e2. 2015. View Article : Google Scholar : PubMed/NCBI
34	Mock K, Preca BT, Brummer T, Brabletz S, Stemmler MP and Brabletz T: The EMT-activator ZEB1 induces bone metastasis associated genes including BMP-inhibitors. Oncotarget. 6:14399–14412. 2015. View Article : Google Scholar : PubMed/NCBI
35	Kurahara H, Takao S, Maemura K, Mataki Y, Kuwahata T, Maeda K, Ding Q, Sakoda M, Iino S, Ishigami S, et al: Epithelial-mesenchymal transition and mesenchymal-epithelial transition via regulation of ZEB-1 and ZEB-2 expression in pancreatic cancer. J Surg Oncol. 105:655–661. 2012. View Article : Google Scholar : PubMed/NCBI
36	Hashiguchi M, Ueno S, Sakoda M, Iino S, Hiwatashi K, Minami K, Ando K, Mataki Y, Maemura K, Shinchi H, et al: Clinical implication of ZEB-1 and E-cadherin expression in hepatocellular carcinoma (HCC). BMC Cancer. 13:5722013. View Article : Google Scholar : PubMed/NCBI